MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• MacroGenics carries an average analyst rating of Hold from eight firms (1 sell, 4 hold, 3 buy) with a mean 12‑month target of $5.40; recent analyst actions include B. Riley upgrading to Buy with a $9 target and Barclays raising to Overweight with a $6 target.
• The company beat expectations in its latest quarter—EPS of ($0.22) vs. ($0.42) est. and revenue of $41.23M vs. $27.81M est.—but remains unprofitable and sell‑side consensus projects roughly –1.2 EPS for the year.
• Shares trade around $3.19 (12‑month range $1.18–$3.88) with a market cap near $203M, and roughly 96.9% of the stock is owned by hedge funds and other institutional investors.

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has received an average rating of "Hold" from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $5.40.

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of MacroGenics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Zacks Research downgraded shares of MacroGenics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, January 1st. Citigroup reiterated a "market perform" rating on shares of MacroGenics in a research report on Tuesday, February 24th. B. Riley Financial raised shares of MacroGenics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $3.00 to $9.00 in a research note on Friday, April 10th. Finally, Barclays increased their target price on MacroGenics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Monday.

Institutional Investors Weigh In On MacroGenics

Several hedge funds have recently bought and sold shares of the business. R Squared Ltd purchased a new position in MacroGenics during the 4th quarter valued at about $26,000. Engineers Gate Manager LP acquired a new stake in shares of MacroGenics during the second quarter worth approximately $28,000. SG Americas Securities LLC grew its position in MacroGenics by 55.9% during the third quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 6,161 shares in the last quarter. Walleye Capital LLC acquired a new position in MacroGenics in the 2nd quarter valued at approximately $30,000. Finally, Cresset Asset Management LLC lifted its position in MacroGenics by 52.3% in the 2nd quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 9,172 shares in the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Stock Up 0.3%

Shares of NASDAQ MGNX opened at $3.19 on Friday. MacroGenics has a 12 month low of $1.18 and a 12 month high of $3.88. The company has a market cap of $202.76 million, a price-to-earnings ratio of -2.73 and a beta of 1.09. The business has a fifty day simple moving average of $2.78 and a 200-day simple moving average of $2.03.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.20. MacroGenics had a negative return on equity of 120.19% and a negative net margin of 49.91%.The firm had revenue of $41.23 million for the quarter, compared to analysts' expectations of $27.81 million. As a group, sell-side analysts expect that MacroGenics will post -1.2 EPS for the current fiscal year.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.